Security Snapshot

Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT) Institutional Ownership

CUSIP: 67080T108

13F Institutional Holders and Ownership History from Q1 2022 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

62

Shares (Excl. Options)

4,519,840

Price

$7.73

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, par value $0.00001 per share
Symbol
NVCT on Nasdaq
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
4,519,840
Latest holder snapshot 5 signals
Total 13F value
$34,936,893
Portfolio coverage rank
0%
Share change
+268,584
Value change
+$2,076,848
Number of holders
62
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
32,314,196
SEC-reported price per share
$18.44
Insider filing price
$18.44
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 67080T108.
  • 62 institutions reported positions in Q1 2026.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 62 to 27 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $34,936,893 to $49,419,161.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 62 institutions filings for Q1 2026.

Open SEC evidence

Security key

67080T108

Latest holder period

Q1 2026

13F holders

62

13D/G owners

1

CIK / CUSIP context first

Open Q1 2026 holders NVCT full holder history Nuvectis Pharma, Inc. SEC filings Nuvectis Pharma, Inc. company facts Nuvectis Pharma, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
NVCT
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Soleus Private Equity Fund III, L.P. 5.1% $30,389,563 1,648,024 Soleus Capital Management, L.P. 04 Aug 2026

As of 31 Mar 2026, 62 institutional investors reported holding 4,519,840 shares of Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT). This represents 14% of the company’s total 32,314,196 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
14%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 2.4% 764,441 -2.3% 0% $5,909,128
VANGUARD CAPITAL MANAGEMENT LLC 2% 659,879 0% 0% $5,100,865
IRIDIAN ASSET MANAGEMENT LLC/CT 2% 651,757 +11% 2% $5,038,082
Occam Crest Management LP 1.3% 407,147 +7.1% 2% $3,147,246
GEODE CAPITAL MANAGEMENT, LLC 1.2% 384,105 +5.5% 0% $2,969,729
BALDWIN WEALTH PARTNERS LLC/MA 1.2% 378,625 -2.8% 0.21% $2,926,771
STATE STREET CORP 0.52% 166,516 +7.7% 0% $1,287,169
NORTHERN TRUST CORP 0.38% 124,212 +6.7% 0% $960,159
VANGUARD FIDUCIARY TRUST CO 0.36% 114,842 0% 0% $887,729
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.33% 105,286 -22% 0% $813,861
VANGUARD PORTFOLIO MANAGEMENT LLC 0.29% 92,154 0% 0% $712,350
CITADEL ADVISORS LLC 0.24% 78,425 0% $606,225
OPPENHEIMER & CO INC 0.23% 73,566 0% 0.01% $568,665
FORBES J M & CO LLP 0.18% 59,000 0% 0.04% $456,070
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.15% 49,645 +13% 0% $383,756
GOLDMAN SACHS GROUP INC 0.13% 41,124 +55% 0% $317,889
UBS Group AG 0.12% 38,563 +360% 0% $298,092
Bank of New York Mellon Corp 0.09% 30,315 -4.2% 0% $234,332
MARSHALL WACE, LLP 0.09% 29,223 0% $225,894
CIBC Bancorp USA Inc. 0.08% 24,883 0% $192,346
MORGAN STANLEY 0.07% 22,568 -19% 0% $174,451
Austin Wealth Management, LLC 0.06% 20,125 0% 0.03% $153,956
MARTINGALE ASSET MANAGEMENT L P 0.06% 18,024 0% $139,326
Nuveen, LLC 0.05% 16,749 0% 0% $129,470
EDMOND DE ROTHSCHILD HOLDING S.A. 0.05% 15,170 0% 0% $117,264

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
18
Latest
Q1 2026
Rows shown
1-18 of 18
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 2,686,464 $49,419,161 +$9,110,600 $18.39 27
2026 Q1 4,519,840 $34,936,893 +$2,076,848 $7.73 62
2025 Q4 4,238,693 $32,029,225 +$4,308,822 $7.55 47
2025 Q3 3,694,801 $22,240,671 +$875,366 $6.02 52
2025 Q2 3,242,656 $24,212,274 +$8,414,990 $7.47 46
2025 Q1 2,047,125 $20,049,463 +$7,527,323 $9.77 33
2024 Q4 1,320,778 $7,145,290 +$1,393,786 $5.41 31
2024 Q3 1,049,389 $6,599,330 -$771,215 $6.29 31
2024 Q2 1,205,075 $7,627,698 -$2,433,916 $6.33 40
2024 Q1 1,561,977 $12,807,385 +$393,490 $8.20 40
2023 Q4 1,513,319 $12,620,464 +$1,886,095 $8.34 36
2023 Q3 1,277,304 $16,463,587 +$85,915 $12.89 33
2023 Q2 1,252,927 $20,033,227 +$12,444,259 $15.97 37
2023 Q1 483,928 $6,343,634 -$3,188,708 $13.11 13
2022 Q4 983,925 $7,378,970 +$968,656 $7.50 11
2022 Q3 1,417,003 $10,047,000 +$5,345,357 $7.09 9
2022 Q2 643,014 $7,201,000 +$370,284 $11.20 10
2022 Q1 628,110 $4,654,000 +$4,654,000 $7.40 7
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .